The California-based biotech continued its rocket-like ascent in 2015–just two years ago it ranked No. 250 on the 500–due to booming sales of its breakthrough Hepatitis C medications. Those drugs–Sovaldi and Harvoni–which cost a fortune, but also cure a chronic, devastating disease, sparked a national debate on drug pricing. They also drove Gilead’s bottom and top lines in 2015–revenues and profits jumped 31% and 50%, respectively. John Milligan, Gilead’s new CEO faces rockier road in 2016: the competition is stiffer and IP challenges and pricing pressures loom.
News about Gilead Sciences
The blockbuster public offering pegs Allogene's market value at more than $2 billion.
Celgene and Novartis are among the companies accused of thwarting generic drugs.
On hot technologies like CRISPR and CAR-T, China has a leg up, Goldman says.
The new cure could be a boon to poorer nations.